A pharmacokinetics study to evaluate drug–drug interactions between fipaxalparant and concomitant medications in healthy participants
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1621 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yang Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc. (formerly Horizon Therapeutics plc), South San Francisco, California, USA. Hauptthemen laut MEDLINE: Rifampin, Itraconazole, Indoles, Pyridones. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Amgen Inc. (formerly Horizon Therapeutics plc).
Abstract (Originalsprache)
Fipaxalparant, a small molecule and negative allosteric modulator of lysophosphatidic acid receptor 1, is being evaluated in phase 2 clinical trials of idiopathic pulmonary fibrosis (IPF) and diffuse cutaneous systemic sclerosis. This phase 1, open‐label, crossover, 3‐cohort study in healthy adults evaluated mutual drug–drug interactions (DDIs) between fipaxalparant and the IPF medications pirfenidone and nintedanib, as well as the effects of itraconazole (P‐glycoprotein inhibitor) and rifampin (potent organic anion transporting polypeptide [OATP] inhibitor) on fipaxalparant. Participants received a single oral dose of fipaxalparant 300 mg. Overall, 16, 20, and 15 participants completed the study in cohorts 1, 2, and 3, respectively. The study demonstrated no relevant mutual DDIs between fipaxalparant and pirfenidone/nintedanib at clinical doses. There was no effect of itraconazole 400 mg on fipaxalparant exposure. A single rifampin 600 mg dose caused 1.48‐fold and 1.86‐fold increases in fipaxalparant C max and AUC 0–∞ , respectively. Treatment‐emergent adverse events were mild/moderate with fipaxalparant alone or with the other study drugs. Overall, fipaxalparant absorption in vivo occurs independently of the P‐glycoprotein–mediated gut efflux pathway, and fipaxalparant is a clinically relevant OATP substrate. Results of this DDI study will inform the management of concomitant medications of ongoing/future trials of fipaxalparant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amgen Inc. (formerly Horizon Therapeutics plc), South San Francisco, California, USA.
- Amgen Inc. (formerly Horizon Therapeutics plc), Deerfield, Illinois, USA.
- Amgen Inc. (formerly Horizon Therapeutics plc), Gaithersburg, Maryland, USA.
Förderung
- Amgen Inc. (formerly Horizon Therapeutics plc)
Zitieren
APA
Song, Y., Hudson, K., Ye, Z., Hawley, L., Pandey, B., Zarzoso, J., Rogowski, J., Sun, Y., A Rees, W., & Xin, Y. (2025). A pharmacokinetics study to evaluate drug–drug interactions between fipaxalparant and concomitant medications in healthy participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1621
Vancouver
Song Y, Hudson K, Ye Z, Hawley L, Pandey B, Zarzoso J, et al. A pharmacokinetics study to evaluate drug–drug interactions between fipaxalparant and concomitant medications in healthy participants. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1621
BibTeX
@article{Song2025,
author = {Song, Yang and Hudson, Krischan and Ye, Zhan and Hawley, Lisa and Pandey, Brajesh and Zarzoso, Jennifer and Rogowski, John and Sun, Yajing and A Rees, William and Xin, Yan},
title = {A pharmacokinetics study to evaluate drug–drug interactions between fipaxalparant and concomitant medications in healthy participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1621}
}
EUVIMED